(Q42641590)

English

A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch

scientific article published on 27 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

author name string

Ivan Berlin

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Ian M Hunneyball

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Doris Greiling

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Stephen P Jones

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hermann Fuder

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hans-Detlev Stahl

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

223

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

89-98

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Monoamine oxidases and tobacco smoking

2 references

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Mortality in relation to smoking: 50 years' observations on male British doctors

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Inhibition of monoamine oxidase B in the brains of smokers

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Brain monoamine oxidase A inhibition in cigarette smokers

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Low monoamine oxidase B in peripheral organs in smokers

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Current pharmacological treatments for nicotine dependence

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase inhibition for tobacco pharmacotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Effects of selegiline (L-deprenyl) during smoking and short-term abstinence

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Signs and symptoms of tobacco withdrawal.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Neurobiological substrates for the dark side of compulsivity in addiction

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase and tobacco dependence.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Irreversible inhibition of monoamine oxidase by some components of cigarette smoke

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2692-2

21 January 2018

Antidepressants for smoking cessation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoamine oxidase A and B activities in heavy smokers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nicotine receptor partial agonists for smoking cessation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nicotine replacement therapy for smoking cessation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22451094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-012-2692-2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42641590&oldid=2205571156"